Vibalogics Risk Report

🛡️ financial & liquidity

Vibalogics has been involved in significant financial activities, particularly related to mergers and acquisitions. These events reflect ongoing efforts to sustain and enhance their financial standing and operational capabilities.

• Recipharm acquired Vibalogics, bolstering its biologics business 🗓 March 2, 2024.
• Recipharm expanded its service offering by acquiring Vibalogics and Arranta Bio 🗓 February 28, 2022.
• The site of the Vibalogics campus was sold for $76 million, indicating a significant increase in property value 🗓 January 3, 2022.
• A private equity firm acquired Vibalogics, aiming to capitalize on the demand for complex viral products 🗓 May 30, 2019.

🏗️ operational & business continuity

Vibalogics has made strategic efforts to ensure continued business operations, focusing on expanding and enhancing its operational capabilities in the United States. The company's initiatives have been centered on manufacturing expansion and site relocations.

• Vibalogics invested $150 million in launching a virotherapy plant, marking a major expansion into the U.S. market 🗓 November 17, 2020.
• The company relocated to a long-vacant Cisco property in Boxborough, repurposing the site for its operations 🗓 November 23, 2020.

📜 innovation & r&d

The collaborative efforts of Vibalogics with other biotech companies emphasize its commitment to innovation and the development of cutting-edge solutions in virotherapy and other related fields.

• Vibalogics partnered with Sirion Biotech to enhance its innovation capabilities in biotechnology 🗓 September 27, 2017.